Compare Nuwellis Inc (NUWE) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Zscaler Inc — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Zscaler Inc trades at $231 (market cap $35.35B). The key difference: Zscaler Inc is far larger — about 16068.2× Nuwellis Inc's market cap, and Zscaler Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Zscaler Inc for 41 Days on average.
| NUWE | ZS | |
|---|---|---|
Market Cap | $2.20M | $35.35B |
Volume | 121,544 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $146.65 | $336.27 |
52-Week Low | $0.68 | $118.05 |
Typical Hold Time | 26 Days | 41 Days |
Enterprise Value | -$1.52M | $33.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Zscaler (ZS) trades at $213.55, up 0.61% with strong technical momentum as the stock approaches resistance near $216. The company demonstrates robust revenue growth, increasing from $1.1B in 2022 to $2.67B in 2025, while narrowing net losses from -$390M to -$41M. Recent earnings beats and 79.6% analyst buy ratings support positive sentiment, though negative profitability metrics and high valuation multiples present challenges.
The outlook remains cautiously optimistic with a $222.83 consensus price target suggesting 4.3% upside potential. Key opportunities include accelerating AI security demand and expanding platform adoption, while risks involve continued profitability challenges, executive transitions, and competitive pressures in the cybersecurity sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
